AI assistant
Altimmune, Inc. — Director's Dealing 2024
Nov 12, 2024
33207_dirs_2024-11-12_f9228f20-777b-4d90-8b22-a9161dadca09.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2024-11-11
Reporting Person: WEAVER GREGORY L (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-11-11 | Stock Options (option to buy) | $7.35 | A | 225000 | Acquired | 2034-11-11 | Common Stock, par value $0.0001 (225000) | Direct |
| 2024-11-11 | Restricted Stock Units | $ | A | 75000 | Acquired | Common Stock, par value $0.0001 (75000) | Direct |
Footnotes
F1: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested
F3: The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.